| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
2,971,000 |
| Market
Cap: |
213.02(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0717 - $0.0717 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Timber Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. Co.'s mid to late-stage programs are: TMB-001, a topical formulation of isotretinoin using Co.'s IPEG™ delivery system for the treatment of moderate to severe subtypes of congenital ichthyosis, a group of rare genetic keratinization disorders that lead to dry, thickened, and scaling skin; and TMB-002, a proprietary topical formulation of rapamycin, is being evaluated for the treatment of facial angiofibromas in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lucchese Joseph |
EVP & CFO |
• • – |
2023-08-20 |
4 |
A |
$0.00 |
$0 |
D/D |
35,193 |
35,193 |
|
- |
|
| Mendelsohn Alan |
EVP & CMO |
• • – |
2023-08-20 |
4 |
A |
$0.00 |
$0 |
D/D |
35,193 |
35,393 |
|
- |
|
| Koconis John |
CEO & Chairman |
• • – |
2023-08-20 |
4 |
A |
$0.00 |
$0 |
D/D |
70,385 |
70,785 |
|
- |
|
| Gaal Lubor |
Director |
• • – |
2023-04-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,100 |
6,100 |
|
- |
|
| Sitar Edward J |
Director |
• • – |
2023-04-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,327 |
11,127 |
|
- |
|
| Pirozzi Gianluca |
Director |
• • – |
2023-04-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,100 |
6,100 |
|
- |
|
| Cohen David E |
Director |
• • – |
2023-04-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,100 |
6,100 |
|
- |
|
| Sitar Edward J |
Director |
– • – |
2022-12-15 |
4 |
A |
$1.63 |
$4,073 |
D/D |
2,500 |
5,800 |
|
- |
|
| Gaal Lubor |
Director |
– • – |
2022-04-15 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
|
- |
|
| Cohen David E |
Director |
– • – |
2022-04-15 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
|
- |
|
| Sitar Edward J |
Director |
– • – |
2022-04-15 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
165,000 |
|
- |
|
| Pirozzi Gianluca |
Director |
– • – |
2022-04-15 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
|
- |
|
| Koconis John |
CEO & President |
• • – |
2021-12-15 |
4 |
B |
$0.38 |
$7,686 |
D/D |
20,000 |
20,000 |
2.81 |
- |
|
| Mendelsohn Alan |
Chief Medical Officer |
• – – |
2021-11-23 |
4 |
B |
$0.47 |
$4,700 |
D/D |
10,000 |
10,000 |
2.66 |
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-09-02 |
4 |
S |
$0.94 |
$210,960 |
D/D |
(225,000) |
3,508,567 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-09-01 |
4 |
S |
$0.92 |
$138,866 |
D/D |
(150,500) |
3,733,567 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-08-31 |
4 |
S |
$0.91 |
$136,740 |
D/D |
(150,000) |
3,884,067 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-08-30 |
4 |
S |
$0.93 |
$92,660 |
D/D |
(100,000) |
4,034,067 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-08-26 |
4 |
S |
$0.92 |
$91,840 |
D/D |
(100,000) |
4,134,067 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-08-25 |
4 |
S |
$0.91 |
$91,260 |
D/D |
(100,000) |
4,234,067 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-08-24 |
4 |
S |
$0.93 |
$92,530 |
D/D |
(100,000) |
4,334,067 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-08-20 |
4 |
S |
$0.91 |
$45,395 |
D/D |
(50,000) |
4,434,067 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-08-19 |
4 |
S |
$0.95 |
$47,700 |
D/D |
(50,000) |
4,484,067 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-08-18 |
4 |
S |
$1.00 |
$75,075 |
D/D |
(75,000) |
4,534,067 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-06-15 |
4 |
S |
$1.26 |
$35,924 |
D/D |
(28,450) |
4,609,067 |
|
- |
|
84 Records found
|
|
Page 1 of 4 |
|
|
